Literature DB >> 9017356

Time-action profile of inhaled insulin.

L Heinemann1, T Traut, T Heise.   

Abstract

We compared the pharmacodynamics of insulin after inhalation of 99 U microcrystalline solid insulin and subcutaneous injection of 10 U regular insulin and intravenous injection of 5 U regular insulin. The time-action profiles of the three insulin administrations were studied in 11 healthy volunteers using the euglycaemic glucose clamp technique. The insulins were administered to each volunteer on three separate occasions in random order. Onset of action, assessed as glucose infusion rate, after insulin inhalation was substantially more rapid than after subcutaneous injection and half-maximal action was reached earlier (31 +/- 17 vs 54 +/- 12 min; p < 0.001). Maximal metabolic response was reached earlier after insulin inhalation in comparison to subcutaneous injection (108 +/- 49 vs 147 +/- 53 min; p < 0.001). The maximal glucose infusion rate after inhalation of insulin was lower than after subcutaneous insulin injection (6.2 +/2- 2.4 vs 9.1 +/- 2.5 mg kg-1 min-1; p < 0.001). The glucose infusion rates in the first 60 min after inhalation were significantly greater than after insulin injection (area under the glucose infusion rate curve: 0.23 +/- 0.12 vs 0.13 +/- 0.08 g kg-1 60 min-1; p < 0.001). However, the total metabolic effect after inhalation was significantly lower than after insulin injection (1.44 +/- 0.68 vs 1.90 +/- 0.47 g kg-1 360 min-1; p < 0.001). Relative effectiveness of inhaled insulin calculated with regard to the data from the intravenous insulin application was 9.5 +/- 4.1% and of the subcutaneous insulin application was 7.6 +/- 2.9%. With its rapid onset of action, inhaled insulin might have potential for clinical use.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9017356     DOI: 10.1002/(SICI)1096-9136(199701)14:1<63::AID-DIA298>3.0.CO;2-F

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  22 in total

Review 1.  Sustained release drug delivery to the lungs: an option for the future.

Authors:  J G Hardy; T S Chadwick
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 2.  Modern pharmacotherapies for type 2 diabetes mellitus.

Authors:  S H Hsia
Journal:  J Natl Med Assoc       Date:  2001-09       Impact factor: 1.798

Review 3.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

4.  Real-world trials to answer real-world questions.

Authors:  Nick Freemantle; Lawrence Blonde; Bjorn Bolinder; Robert A Gerber; F D Richard Hobbs; Luc Martinez; Stuart Ross
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  The new diabetes inhalers: new tools for the clinician.

Authors:  William T Cefalu
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

Review 6.  Particle transport and deposition: basic physics of particle kinetics.

Authors:  Akira Tsuda; Frank S Henry; James P Butler
Journal:  Compr Physiol       Date:  2013-10       Impact factor: 9.090

7.  The effect of exercise on the absorption of inhaled human insulin in healthy volunteers.

Authors:  Astrid H Petersen; Gerd Köhler; Stefan Korsatko; Andrea Wutte; Manfred Wonisch; Agnes Mautner; Birgitte B Rønn; Per Clauson; Torben Laursen; Per Wollmer; Thomas R Pieber
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

Review 8.  Novel drug delivery systems for insulin: clinical potential for use in the elderly.

Authors:  Joël Belmin; Paul Valensi
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 9.  Transdermal drug delivery of insulin with ultradeformable carriers.

Authors:  Gregor Cevc
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Controlled release of biologics for the treatment of type 2 diabetes.

Authors:  Caslin A Gilroy; Kelli M Luginbuhl; Ashutosh Chilkoti
Journal:  J Control Release       Date:  2015-12-02       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.